COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
The present invention provides novel compositions comprising a combination of a 5-HT 3 receptor antagonist and a selective dopamine D 2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT 3 receptor antagonist ondansetron and a selective dopamine D 2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subject's obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.
1 - 20 . (canceled)
21 . A method for treating obsessive, impulsive, and compulsive behavioral activities in a patient, said method comprising the step of:
administering about 0.2 mg to about 0.8 mg of ondansetron to the patient.
22 . The method of claim 21 , further comprising the step of administering a monoamine receptor antagonist to the patient.
23 . The method of claim 22 , wherein the monoamine receptor antagonist is a selective dopamine D2 receptor antagonist.
24 . The method of claim 23 , wherein the selective dopamine D2 receptor antagonist is an atypical antipsychotic agent.
25 . The method of claim 23 , wherein the selective dopamine D2 receptor antagonist is risperidone.